132 related articles for article (PubMed ID: 38451719)
1. Phase separation of SHP2E76K promotes malignant transformation of mesenchymal stem cells by activating mitochondrial complexes.
Kan C; Tan Z; Liu L; Liu B; Zhan L; Zhu J; Li X; Lin K; Liu J; Liu Y; Yang F; Wong M; Wang S; Zheng H
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38451719
[TBL] [Abstract][Full Text] [Related]
2. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
[TBL] [Abstract][Full Text] [Related]
3. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
4. Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation.
Zhu G; Xie J; Kong W; Xie J; Li Y; Du L; Zheng Q; Sun L; Guan M; Li H; Zhu T; He H; Liu Z; Xia X; Kan C; Tao Y; Shen HC; Li D; Wang S; Yu Y; Yu ZH; Zhang ZY; Liu C; Zhu J
Cell; 2020 Oct; 183(2):490-502.e18. PubMed ID: 33002410
[TBL] [Abstract][Full Text] [Related]
5. Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Yang Z; Kondo T; Voorhorst CS; Nabinger SC; Ndong L; Yin F; Chan EM; Yu M; Würstlin O; Kratz CP; Niemeyer CM; Flotho C; Hashino E; Chan RJ
Mol Cell Biol; 2009 Aug; 29(16):4376-93. PubMed ID: 19528235
[TBL] [Abstract][Full Text] [Related]
6. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
Ren Y; Chen Z; Chen L; Woods NT; Reuther GW; Cheng JQ; Wang HG; Wu J
J Biol Chem; 2007 Dec; 282(50):36463-73. PubMed ID: 17942397
[TBL] [Abstract][Full Text] [Related]
7. Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Nabinger SC; Chan RJ
Curr Opin Hematol; 2012 Jul; 19(4):273-9. PubMed ID: 22504523
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
9. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
Zhao H; Agazie YM
BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
[TBL] [Abstract][Full Text] [Related]
11. Role of SHP2 in hematopoiesis and leukemogenesis.
Pandey R; Saxena M; Kapur R
Curr Opin Hematol; 2017 Jul; 24(4):307-313. PubMed ID: 28306669
[TBL] [Abstract][Full Text] [Related]
12. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.
Noël LA; Arts FA; Montano-Almendras CP; Cox L; Gielen O; Toffalini F; Marbehant CY; Cools J; Demoulin JB
Mol Oncol; 2014 May; 8(3):728-40. PubMed ID: 24618081
[TBL] [Abstract][Full Text] [Related]
14. Phase separation ability and phosphatase activity of the SHP1-R360E mutant.
Zhang Q; Kong W; Zhu T; Zhu G; Zhu J; Kong X; Du Y
Biochem Biophys Res Commun; 2022 Apr; 600():150-155. PubMed ID: 35219918
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract][Full Text] [Related]
16. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
Yang Z; Li Y; Yin F; Chan RJ
Exp Hematol; 2008 Oct; 36(10):1285-96. PubMed ID: 18640765
[TBL] [Abstract][Full Text] [Related]
17. Sepsis-induced cardiac mitochondrial dysfunction involves altered mitochondrial-localization of tyrosine kinase Src and tyrosine phosphatase SHP2.
Zang QS; Martinez B; Yao X; Maass DL; Ma L; Wolf SE; Minei JP
PLoS One; 2012; 7(8):e43424. PubMed ID: 22952679
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
19. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
[TBL] [Abstract][Full Text] [Related]
20. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
